Last Updated: September 28, 2026

RELGAABI Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Relgaabi, and what generic alternatives are available?

Relgaabi is a drug marketed by Sciegen Pharms and is included in one NDA.

The generic ingredient in RELGAABI is gabapentin. Eighty-nine suppliers are listed for this compound. Additional details are available on the gabapentin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Relgaabi

A generic version of RELGAABI was approved as gabapentin by ACTAVIS ELIZABETH on September 12^th, 2003.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for RELGAABI?
What are the global sales for RELGAABI?
What is Average Wholesale Price for RELGAABI?

Summary for RELGAABI

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for RELGAABI

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sciegen Pharms	RELGAABI	gabapentin	CAPSULE;ORAL	204989-001	Feb 18, 2016	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Sciegen Pharms	RELGAABI	gabapentin	CAPSULE;ORAL	204989-003	Feb 18, 2016	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Sciegen Pharms	RELGAABI	gabapentin	CAPSULE;ORAL	204989-004	Mar 6, 2026	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Sciegen Pharms	RELGAABI	gabapentin	CAPSULE;ORAL	204989-002	Feb 18, 2016	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.